Glioblastoma Multiforme (GBM) Pipeline Analysis (2024) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Oncotelic, Ascletis, AstraZeneca, Bayer, BioMimetix, BioNTech, Karyopharm, Celgene, Chimerix

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 195+ key pharma and biotech companies are working on 210+ pipeline drugs in the Glioblastoma Multiforme therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Glioblastoma Multiforme Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Glioblastoma Multiforme Therapeutics Market.

The report provides a detailed description of the Glioblastoma Multiforme drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the Glioblastoma Multiforme Clinical Trial Activities and Regulatory Developments in the domain @
https://www.delveinsight.com/report-store/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Glioblastoma Multiforme Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Glioblastoma Multiforme therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Glioblastoma Multiforme treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Glioblastoma Multiforme drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Glioblastoma Multiforme treatment market.

Learn More about the Clinical and Commercial Development Activities in the Glioblastoma Multiforme Therapeutics Domain @
https://www.delveinsight.com/report-store/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Glioblastoma Multiforme Therapeutics Analysis
Treatment for GBM usually includes a combination of surgery, chemotherapy, radiation, or stereotactic radiosurgery. Surgery is usually one of the most important aspects of treatment, although rarely used alone. Since glioblastomas develop very rapidly, they are often difficult to remove in their entirety. Therefore, surgery is performed to achieve a maximum safe resection - removing as much of the tumor as possible while preserving the patient's brain function and sparing healthy tissues. Residual cancer cells can be targeted with additional treatments, such as chemotherapy or radiation therapy, after surgery. Radiation therapy and chemotherapy usually follow surgery once the diagnosis or name of the tumor is determined. These treatments are called adjuvant treatments. Because this multi-specialty approach can cause several side effects, steroids are often provided as another essential part of glioblastoma treatment, used to help alleviate the side effects of other therapies.

The first-line treatment of GBM involves drug therapy following surgery, which includes Temozolomide + Radiation Therapy and Temozolomide Monotherapy. While the second-line treatment for GBM includes Bevacizumab Monotherapy, Bevacizumab Combination Therapy, Temozolomide (Both as Combination and Monotherapy), and Other Systemic Therapies (Concomitant and Adjuvant).

There are approx. 195+ key companies developing therapies for Glioblastoma Multiforme (GBM). Currently, Oncotelic Therapeutics is leading the therapeutics market with its Glioblastoma Multiforme drug candidates in the most advanced stage of clinical development.

Glioblastoma Multiforme Companies in the Therapeutics Market Include:
Some of the key companies in the Glioblastoma Multiforme therapeutics market includes3-V Biosciences, ACADIA Pharmaceuticals, Acerta Pharma, Aivita Biomedical, Array Biopharma, Ascletis, AstraZeneca, Autotelic Therapeutics, Bayer, BioMimetix, BioNTech, Bristol Myers Squibb, Celgene Corporation, Chimerix, CNS Pharmaceutical, Cytogel, Denovo Biopharma, DNAtrix, Doule bond Pharmaceuticals, Eisai and Merck Sharp & Dohme, Enterome, Epitopoietic Research Corporation (ERC), Forma Therapeutics, Genenta Science, Immatics N.V, Immunomic Therapeutics, Imvax, Inovio Pharmaceuticals, Istari Oncology, Karyo Pharma, Karyopharm Therapeutics, Kazia Therapeutics, Kintara Therapeutics, Laminar Pharmaceuticals, Mayo Clinic, Medicenna Therapeutics, MedImmune, Merck, MimiVax, Neugate Theranostics, Northwest Therapeutics, Novartis, Noxxon Pharma, Oblato, Oncotelic Therapeutics, Orphelia Pharma, Pfizer, Philogen, Roche, SonALAsense, TME Pharma, VBI Vaccines, Xgene Pharmaceutical, Yumanity Therapeutics, and many others. These companies collectively contribute diverse expertise, innovative approaches, and dedicated efforts to address the complexities and challenges associated with combating Glioblastoma Multiforme, a critical area within the field of oncology.

Emerging and Marketed Glioblastoma Multiforme Therapies Covered in the Report Include:
Afatinib: Boehringer Ingelheim, AV-GBM-1: Aivita Biomedical, Avastin: Genentech, AZD1390: AstraZeneca, Crenolanib: AROG Pharmaceuticals, CYNK 001: Celularity, DCVax-L: Northwest Pharmaceuticals, Durvalumab (MEDI4736): MedImmune, G207: Treovir, ITI-1000 (pp65 DC Vaccine): Immunomic Therapeutics, LAM561 (2-OHOA): Laminar Pharmaceuticals, MDNA55: Medicenna Therapeutics, Ofranergene obadenovec (VB-111): VBL Therapeutics, ONC201: Chimerix, Onfekafuspalfa: Philogen, Paxalisib (GDC-0084): Kazia Therapeutics, PVSRIPO: Istari Oncology, Regorafenib: Bayer Healthcare, Research program: protein arginine N-methyltransferase 5 inhibitors: Jubilant Therapeutics, Selinexor (KPT-330): Karyopharm Therapeutics, Selinexor: Karyopharm Therapeutics, Tasadenoturev (DNX-2401): DNAtrix, Temodar/Temodal: Merck, Trabedersen: Oncotelic Therapeutics, Trans Sodium Crocetinate: Diffusion Pharmaceuticals, TVB2640:Ascletis Pharma, VAL-083 (Dianhydrogalactitol): Kintara Therapeutics, VBI-1901: VBI Vaccines, YTX7739: Yumanity Therapeutics, and many more.

Get an in-depth Assessment of the Emerging Therapies and Glioblastoma Multiforme Companies Actively Working in the Market @
https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

The Report Covers the Emerging Glioblastoma Multiforme Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates

Route of Administration
Glioblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type
Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Request for Sample PDF to Understand More About the Glioblastoma Multiforme Treatment Outlook and Future Perspectives @
https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Glioblastoma Multiforme Current Treatment Patterns
4. Glioblastoma Multiforme - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Glioblastoma Multiforme Late-Stage Products (Phase-III)
7. Glioblastoma Multiforme Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Glioblastoma Multiforme Discontinued Products
13. Glioblastoma Multiforme Product Profiles
14. Glioblastoma Multiforme Companies
15. Glioblastoma Multiforme Drugs
16. Dormant and Discontinued Products
17. Glioblastoma Multiforme Unmet Needs
18. Glioblastoma Multiforme Future Perspectives
19. Glioblastoma Multiforme Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings @
https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.